-
Has the Expert Committee of the Food and Drug Administration unanimously approved Eli Lilly's new drug? Will Alzheimer's patients have new choices?
On June 10th, Lilly's Alzheimer's disease (AD) drug Donanemab was unanimously approved by the FDA's Advisory Committee on Peripheral and Central Nervous System Drugs (PCNS).